Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

Name: Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital
Start: 2022-10-05T13:30:00-04:00
End: 2022-10-05T14:30:00-04:00

Reducing Relapse Risk After Transplant Using Jakafi With Gabriela Hobbs, MD, Massachusetts General Hospital

HealthTree Podcast for AML

Oct 05, 2022 / 01:30PM EDT

Listen to Podcast

Event Description

IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728.

*You need to join by phone if you want to ask Dr. Hobbs your questions.*

Allogeneic stem cell transplantation is the only curative option for patients battling acute myeloid leukemia. However, a significant number of patients will relapse after transplant. Innovative research and therapies are needed in order to improve outcomes in AML patients.

The drug Jakafi (ruxolitinib), a kinase inhibitor, is being explored in a current clinical trial as it may help reduce the risk of relapse. Other therapies such as pre-emptive donor lymphocyte infusions, hypomethylating agents and FLT3 inhibitors combined with donor lymphocyte infusions, CAR T-cell and CAR-NK cells are some of the relapse prevention treatment strategies being explored.

Join us live on Wednesday, October 5th at 1:30 pm EST to hear from Dr. Gabriela Hobbs with Massachusetts General Hospital who will be discussing her clinical trial using Jakafi (ruxolitinib) after allogeneic stem cell transplant as well as other therapies to reduce relapse risk. There will be time at the end of the show to ask Dr. Hobbs your questions directly!

Thank you to our episode sponsor, Bristol Myers Squibb.

Schedule & Agenda

Welcome

01:30PM

Kerith Amen

Welcome, Announcements & Introduction

01:30PM

Kerith Amen

Welcome

Welcome, Announcements & Introduction

Interview

01:35PM

Gabriela Hobbs

Dr. Hobbs will discuss her clinical trial using Jakafi (ruxolitinib) to help reduce the risk of relapse after stem cell transplantation, as well as other relapse prevention therapies.

01:35PM

Gabriela Hobbs

Interview

Dr. Hobbs will discuss her clinical trial using Jakafi (ruxolitinib) to help reduce the risk of relapse after stem cell transplantation, as well as other relapse prevention therapies.

Q&A

02:20PM

Audience

Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Hobbs questions about what was discussed during our interview today.

02:20PM

Audience

Q&A

Audience is able to call in to the radio show, (515) 602-9728, to ask Dr. Hobbs questions about what was discussed during our interview today.

Speakers & Moderators

Gabriela Hobbs

Boston, MA

Dr. Gabriela Hobbs ia a hematology-oncology physician who specializes in the care of patients with myeloproliferative neoplasms (MPN), chronic myeloid leukemia and leukemia. She is an active clinical researcher, leads the MPN research program at Massachusetts General Hospital and also participates in translational research for MPN. In addition, Dr. Hobbs is the clinical director for the adult leukemia service at MGH.

Read Bio

Kerith Amen

New Orleans, Louisiana

Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.

Read Bio